CONSORZIO ONCOTECH

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Established: 2001-01-01

Employees: -

Market Cap: -

Website: https://www.oncotech.org/oncotech/home/

Clinical Trials

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Phase 2

Completed

Conditions: Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Interventions: Drug: Avelumab

First Posted Date: 2019-03-26

Last Posted Date: 2024-02-01

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 67

Registration Number: NCT03891238

Locations: 🇮🇹
Istituto Europeo di Oncologia, Milano, Italy
🇮🇹
Fondazione Salvatore Maugeri, Pavia, Italy
🇮🇹
Arcispedale Santa Maria Nuova Di Reggio Emilia, Reggio Emilia, Italy

and more 18 locations

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

Phase 2

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Netupitant/Palonosetron

First Posted Date: 2019-03-05

Last Posted Date: 2019-03-05

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 150

Registration Number: NCT03862144

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Phase 2

Conditions: Castration-resistant Prostate Cancer
Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2017-11-29

Last Posted Date: 2017-12-14

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 220

Registration Number: NCT03356912

Locations: 🇮🇹
University Federico II of Naples, Naples, Italy

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Phase 1

Conditions: Kidney Cancer
Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Drug: Placebo
Drug: Isoquercetin

First Posted Date: 2015-05-18

Last Posted Date: 2017-01-18

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 104

Registration Number: NCT02446795

Locations: 🇮🇹
Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
🇮🇹
Fondazione G. Pascale, Naples, Italy
🇮🇹
University Federico II of Naples, Naples, Italy

and more 2 locations

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Phase 3

Conditions: Metastatic Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Locally Advanced Malignant Neoplasm

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Fulvestrant

First Posted Date: 2015-03-31

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 745

Registration Number: NCT02404051

Locations: 🇮🇹
Azienda Ospedaliera Policlinico di Bari, Bari, Italy
🇮🇹
A.O.R.N.A.S. Garibaldi Nesima di Catania, Catania, Italy
🇮🇹
Presidio Ospedaliero Antonio Perrino, Brindisi, Italy

and more 38 locations

Overcoming Endocrine Resistance in Metastatic Breast Cancer

Phase 3

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Placebo Lapatinib
Drug: Aromatase Inhibitors
Drug: Lapatinib

First Posted Date: 2015-03-20

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 396

Registration Number: NCT02394496

Locations: 🇮🇹
Ospedale Sacro Cuore - Don Calabria U.O.C. Oncologia Medica, Negrar, Verona, Italy
🇮🇹
Azienda Ospedaliera Treviglio-Caravaggio U.O. Oncologia Medica, Treviglio, Bergamo, Italy
🇮🇹
Presidio Ospedaliero di Vallo della Lucania U.O. Oncologia Medica, Vallo Della Lucania, Salerno, Italy

and more 66 locations

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Phase 3

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant

First Posted Date: 2015-03-09

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 156

Registration Number: NCT02383030

Locations: 🇮🇹
Ospedale 'Felice Lotti' - Azienda USL 5 di Pisa U.O. di Oncologia Medica, Pontedera, Pisa, Italy
🇮🇹
Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
🇮🇹
Ospedale Unico Versilia U.O. Oncologia Medica, Lido Di Camaiore, Lucca, Italy

and more 17 locations

Observation of Medical Treatments in MBC HER2-negative Patients

Conditions: Metastatic Breast Cancer

Interventions: Other: Observation of treatment management

First Posted Date: 2015-02-19

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 1500

Registration Number: NCT02365831

Locations: 🇮🇹
A.O. San Gerardo, Monza, Italy

Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting

Conditions: Metastatic Breast Cancer

First Posted Date: 2014-11-06

Last Posted Date: 2023-11-13

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 10000

Registration Number: NCT02284581

Locations: 🇮🇹
Centro di Riferimento Oncologico, Aviano, Italy
🇮🇹
Fondazione del Piemonte per l'Oncologia - I.R.C.C., Candiolo, Italy
🇮🇹
Ospedale Policlinico San Martino IRCCS, Genova, Italy

and more 31 locations

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Lapatinib
Drug: Trastuzumab

First Posted Date: 2014-09-12

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 154

Registration Number: NCT02238509

Locations: 🇮🇹
A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy
🇮🇹
Ospedale Centrale di Bolzano, Bolzano, Italy
🇮🇹
Humanitas Centro Catanese di Oncologia, Catania, Italy

and more 33 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy